目的 系統(tǒng)評價異甘草酸鎂治療抗結(jié)核藥物所致肝損害的療效和安全性。方法 檢索PubMed、EMbase、Cochrane圖書館、Medline、中國學(xué)術(shù)期刊全文數(shù)據(jù)庫（CNKI）、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫（CBM）、萬方數(shù)據(jù)庫和維普數(shù)據(jù)庫，收集國內(nèi)外關(guān)于異甘草酸鎂治療抗結(jié)核藥致肝損害的臨床隨機(jī)對照研究（RCTs），評價納入研究的質(zhì)量并提取數(shù)據(jù)，使用RevMan 5.3軟件進(jìn)行Meta-分析。結(jié)果 共納入14篇RCTs，包括1 202名抗結(jié)核藥致肝損害患者。Meta-分析結(jié)果顯示：異甘草酸鎂在治療抗結(jié)核藥致肝損害總有效率[RR=1.38，95% CI （1.24，1.54），P<0.000 01]、降低丙氨酸氨基轉(zhuǎn)移酶（ALT）[MD=-25.98，95% CI （-34.68，-17.29），P<0.000 01]、天冬氨酸氨基轉(zhuǎn)移酶（AST）[MD=-20.21，95% CI （-24.49，-15.93），P<0.000 01]、總膽紅素（TB）[MD=-9.92，95% CI （-16.41，-3.43），P=0.003]、堿性磷酸酶（ALP）[MD=-13.91，95% CI （-26.03，-1.79），P=0.02]方面均優(yōu)于對照組，差異有統(tǒng)計學(xué)意義，同時不良反應(yīng)發(fā)生率低于對照組[RR=0.51，95% CI （0.27，0.96），P=0.04]。結(jié)論 異甘草酸鎂治療抗結(jié)核藥致肝損害臨床療效較好，可顯著降低患者血清ALT、AST、TB和ALP水平，同時具有較高安全性，但本研究納入文獻(xiàn)多為較低質(zhì)量的小樣本研究，尚需更多高質(zhì)量、大樣本的隨機(jī)對照試驗進(jìn)一步支持。

Objective To evaluate the efficacy and safety of magnesium isoglycyrrhizinate in the treatment of liver injury caused by anti-tuberculosis drugs.Methods PubMed,EMbase,Cochrane Database,Medline,CNKI,the Chinese Biomedical Database (CBM),Wanfang Database and WIP Database were searched to collecte the randomized controlled trials (RCTs) on liver injury patients caused by anti-tuberculosis drugs treated with magnesium isoglycyrrhizin.After screening the literatures,the quality of the included studies and extracted data was evaluated by using the RevMan 5.3 software for meta-analysis.Results A total of 14 RCTs were selected,including 1 202 patients with liver injury caused by anti-tuberculosis drugs.The total effective rate[RR=1.38,95% CI (1.24,1.54),P< 0.000 01],the reduced ALT[MD=-25.98,95% CI (-34.68),-17.29),P< 0.000 01],AST[MD=-20.21,95% CI (-24.49,-15.93),P< 0.000 01],TB[MD=-9.92,95% CI (-16.41,-3.43),P=0.003],ALP[MD=-13.91,95% CI (-26.03,-1.79),P=0.02]were superior to the control group,the difference was statistically significant,and the incidence of adverse reactions was lower than that of the control group[RR=0.51,95% CI (0.27,0.96),P=0.04].Conclusion Magnesium glycyrrhizinate has a good clinical effect in the treatment of liver injury caused by anti-tuberculosis drugs,which can significantly reduce the serum levels of ALT,AST,TB and ALP,and has a higher safety.However,the less quantity of samples,more high-quality and large-sample RCTs are needed to further support.